OCE at ASCO Annual Meeting 2023
FDA Oncology Center of Excellence experts will join colleagues in clinical oncology to participate in panel discussions or present research findings during the American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago and online June 2-6, 2023. All times listed are Central Daylight Time.
Saturday, June 3
1:15-4:15 pm Poster Session: Health Services Research and Quality Improvement
Title: Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets.
Abstract 6595 | Poster 87
Sunday, June 4
8-11 am Poster Session
Title: FDA analysis of toxicity profiles or oral TKIs recently approved for NSCLC based on receipt of prior immune checkpoint inhibitor therapy
Presenter: Yufan Liu
Abstract 9119 | Poster 107
4:15-5 pm Embracing Career Transitions and Professional Growth
Panelist: Jennifer Gao
Location: Women’s Networking Lounge, S502
Monday, June 5
8-11 am Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Title: FDA analysis of treatment efficacy based on etiology of hepatocellular carcinoma
Presenter: May Tun Saung, MD
Abstract 4117 | Poster 438
Title: Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals
Presenter: Naomi Horiba
Abstract 4115 | Poster 436
1:15-4:15 pm Poster Session: Care Delivery and Regulatory Policy
Title: Trends in new and persistent opioid use in older adults with cancer.
Presenter: Collaborators Yale-Mayo CERSI
Abstract 1592 | Poster 186
Title: Trends in U.S and global patient enrollment from 2014 to 2022 in lung cancer clinical trials supporting marketing applications: An FDA analysis.
Presenter: Oladimeji Akinboro
Abstract 1576 | Poster 170
Title: Dosage Optimization in Drug Development: An FDA Project Optimus analysis of postmarketing requirements Issued to repair the cracks
Presenter: Brian Heiss
Abstract 1598 | Poster 192
Tuesday, June 6
Online only publication: Health Services Research and Quality Improvement Track
Enrollment representation of age, race, and ethnicity in ovarian cancer registrational clinical trials (2010-2020): An evaluation by the U.S. Food and Drug Administration.
Authors: Felice Yang, Yue Huang, Catherine Lerro, Wei Liu, Mallorie Fiero, Zhou Feng, Bindu Kanapuru, Timil Patel, Laleh Amiri-Kordestani, Gwynn Ison, Lola Fashoyin-Aje, Paul Kluetz, Harpreet Singh, Donna Rivera